Inhibition of Heme Oxygenase-1 Enhances the Cytotoxic Effect of Gemcitabine in Urothelial Cancer Cells

被引:0
作者
Miyake, Makito [1 ]
Fujimoto, Kiyohide [1 ]
Anai, Satoshi [1 ]
Ohnishi, Sayuri [1 ]
Nakai, Yasushi [1 ]
Inoue, Takeshi [1 ]
Matsumura, Yoshiaki [1 ]
Tomioka, Atsushi [1 ]
Ikeda, Tomohiro [1 ]
Okajima, Eijiro [1 ]
Tanaka, Nobumichi [1 ]
Hirao, Yoshihiko [1 ]
机构
[1] Nara Med Univ, Dept Urol, Nara 6348522, Japan
关键词
Urothelial cancer; heme oxygenase-1; drug resistance; chemotherapy; radiotherapy; gemcitabine; PEGYLATED ZINC PROTOPORPHYRIN; PHASE-II TRIAL; PANCREATIC-CANCER; PLUS CISPLATIN; GENE-EXPRESSION; PROSTATE-CANCER; BLADDER-CANCER; IN-VITRO; THERAPY; CARCINOMA;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Elevated heme oxygenase-1 (HO-1) is associated with resistance to chemo- and radiotherapy through anti-apoptotic function. The present study evaluated whether the HO-I inhibitor, zinc protoporphyrin IX (ZnPP), enhances the cytotoxic effect of gemcitabine in urothelial carcinoma (UC). Materials and Methods: The in vitro cytotoxic effect of combination treatment of gemcitabine and ZnPP on UC cells was examined. The in vivo growth inhibitory effects of intraperitoneal administration of gemcitabine and/or ZnPP on mouse subcutaneous tumours were examined. The apoptotic changes were analysed with the detection of DNA fragmentation and cleaved caspase-3. Results: HO-I was up-regulated by both gemcitabine and irradiation treatment in vitro. ZnPP sensitised the UC cells to both therapies. Enhanced apoptosis was induced by the ZnPP combined with gemicitabine. ZnPP enhanced the antitumour effect of gemcitabine in vivo along with decreased numbers of proliferating cells and increased numbers of apoptotic cells. Conclusion: These findings suggest that ZnPP combined with gemcitabine or irradiation therapy may be an effective therapeutic modality for UC patients.
引用
收藏
页码:2145 / 2152
页数:8
相关论文
共 30 条
  • [1] Combination of PTEN gene therapy and radiation inhibits the growth of human prostate cancer Xenografts
    Anai, Satoshi
    Goodison, Steve
    Shiverick, Kathleen
    Iczkowski, Kenneth
    Tanaka, Motoyoshi
    Rosser, Charles J.
    [J]. HUMAN GENE THERAPY, 2006, 17 (10) : 975 - 984
  • [2] Gemcitabine chemoresistance in pancreatic cancer: Molecular mechanisms and potential solutions
    Andersson, Roland
    Aho, Ursula
    Nilsson, Bo I.
    Peters, Godefridus J.
    Pastor-Anglada, Marcal
    Rasch, Wenche
    Sandvold, Marit L.
    [J]. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2009, 44 (07) : 782 - 786
  • [3] Inhibition of heme oxygenase-1 increases responsiveness of pancreatic cancer cells to anticancer treatment
    Berberat, PO
    Dambrauskas, Z
    Gulbinas, A
    Giese, T
    Giese, N
    Künzli, B
    Autschbach, F
    Meuer, S
    Büchler, MW
    Friess, H
    [J]. CLINICAL CANCER RESEARCH, 2005, 11 (10) : 3790 - 3798
  • [4] Bergman AM, 1996, CLIN CANCER RES, V2, P521
  • [5] Evidence-based standards for cancer pain management
    Dy, Sydney M.
    Asch, Steven M.
    Naeim, Arash
    Sanati, Homayoon
    Walling, Anne
    Lorenz, Karl A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (23) : 3879 - 3885
  • [6] Fang J, 2003, CANCER RES, V63, P3567
  • [7] Enhancement of chemotherapeutic response of tumor cells by a heme oxygenase inhibitor, pegylated zinc protoporphyrin
    Fang, J
    Sawa, T
    Akaike, T
    Greish, K
    Maeda, H
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2004, 109 (01) : 1 - 8
  • [8] Goodman AI, 1997, P SOC EXP BIOL MED, V214, P54
  • [9] The biological and therapeutic importance of gastrin gene expression in pancreatic adenocarcinomas
    Harris, JC
    Gilliam, AD
    McKenzie, AJ
    Evans, SA
    Grabowska, AM
    Clarke, PA
    McWilliams, DF
    Watson, SA
    [J]. CANCER RESEARCH, 2004, 64 (16) : 5624 - 5631
  • [10] Systemic therapy for biliary tract cancers
    Hezel, Aram F.
    Zhu, Andrew X.
    [J]. ONCOLOGIST, 2008, 13 (04) : 415 - 423